Loading...
XNAS
NKTR
Market cap1.16bUSD
Dec 05, Last price  
56.90USD
1D
-1.37%
1Q
41.61%
Jan 2017
363.73%
Name

Nektar Therapeutics

Chart & Performance

D1W1MN
XNAS:NKTR chart
P/E
—
P/S
11.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-39.91%
Rev. gr., 5y
-3.00%
Revenues
98m
+9.22%
126,279,000217,718,000273,027,00090,185,00071,931,000159,039,00071,480,00081,191,000148,921,000200,707,000230,784,000165,436,000307,711,0001,193,323,000114,617,000152,915,000101,907,00092,055,00090,122,00098,427,000
Net income
-119m
L-56.91%
-185,111,000-154,761,000-32,761,000-34,336,000-102,519,000-37,938,000-133,978,000-171,855,000-162,013,000-53,916,000-81,177,000-153,524,000-96,692,000681,313,000-440,667,000-444,440,000-523,837,000-368,198,000-276,056,000-118,961,000
CFO
-176m
L-8.77%
-77,998,000-92,715,000146,302,000-145,782,00039,739,000-55,871,000-113,742,000-129,756,000-38,527,000-142,006,000-73,083,000-117,024,000-80,414,000718,214,000-328,681,000-313,287,000-412,660,000-304,007,000-192,606,000-175,709,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
URL
https://www.nektar.com/
IPO date
May 03, 1994
Employees
216
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT